Last updated 2026-09-04
- Went public on NASDAQ (URGN), May 2017
- Raised $250M debt round, Mar 2026
- Raised $107.5M Follow-on PO, Jun 2024
Total raised
$1.1B
Last: Debt Financing 2026-02
Stage
Public
Founded
2004
Headcount
291
HQ
Ra'anana, Israel
Sector
Health Tech & Life Sciences
About
UroGen Pharma is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company utilizes its proprietary RTGel reverse-thermal hydrogel technology, a sustained-release, hydrogel-based platform, to improve the therapeutic profiles of existing drugs. This technology is designed to enable longer exposure of urinary tract tissue to medications, offering a potentially more effective local treatment option. UroGen's product pipeline includes treatments for low-grade upper tract urothelial cancer (UTUC) and non-muscle invasive bladder cancer (NMIBC).
Funding history · 11 rounds · $1.1B total
14 events/rounds · $1.1B Total Funding: $855.3M in Public Equity, $475.0M in Debt
Mar 2026
Debt Financing
$250.0M
Sep 2024
Debt Financing
$25.0M
Jun 2024
Follow-on PO
$107.5M
Jul 2023
PIPE
$120.0M
Dec 2022
Follow-on PO
$83.4M
Oct 2022
Debt Financing
$25.0M
Mar 2022
Debt Financing
$100.0M
Mar 2021
Debt Financing
$75.0M
Dec 2019
Follow-on PO
$100.0M
Jan 2019
Follow-on PO
$150.0M
Jan 2018
Follow-on PO
$60.0M
Headcount over time
291 employees (2026-09) · 1 point
Offices
Ra'anana, Israel · HQ / main office
Show all offices (1 more)
- Princeton, United States
Q&A
- What was UroGen Pharma's most recent funding round?
- UroGen Pharma completed a Debt Financing round in February 2026, raising $250,000,000 from Pharmakon Advisors.
- When did UroGen Pharma last conduct a public offering?
- UroGen Pharma had a Public Offering in June 2024, raising $107,500,000.
- What is UroGen Pharma's primary focus in terms of therapies?
- UroGen Pharma focuses on urologic oncology therapies, developing novel solutions for specialty cancers and urologic diseases.
- What is RTGel?
- RTGel is UroGen Pharma's proprietary sustained-release, hydrogel-based platform technology designed to improve the therapeutic profiles of existing drugs by enabling longer exposure of urinary tract tissue to medications.
- What are UroGen Pharma's lead product candidates?
- UroGen Pharma's lead product candidates are UGN-101 (mitomycin urothelial gel, known as MitoGel) and UGN-102 (mitomycin intravesical gel, known as VesiGel), which are designed for non-surgical tumor removal and treatment of non-muscle-invasive urothelial cancer.
- When was UroGen Pharma founded?
- UroGen Pharma was founded in April 2004.
- What is the current employee count for UroGen Pharma?
- UroGen Pharma has 201-500 employees.
- What is UroGen Pharma's current market capitalization?
- UroGen Pharma has a market capitalization of $1,096,264,251.
Team · 12
Asher Holzer
Founder · Founder
Liz Barrett
President and Chief Executive Officer
Chris Degnan
Chief Financial Officer
Alison Hardgrove
SVP, Human Resources
Marina Konorty
EVP, Research & Development and Technical Operations
Michael J. Louie
SVP, General Counsel
Jim Ottinger
EVP, Regulatory Affairs and Quality
Mark P. Schoenberg
Chief Medical Officer
Timothy Simon
SVP, Business Development
Jason Smith
General Counsel and Chief Compliance Officer
Arie Belldegrun
Chairman of the Board
Daniel G. Wildman
Independent Director
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2BB2C
Highlights
1 Patents
Tags
oncologydrug-deliverysustained-releaseurologypharmaceuticalsorphan-drugnon-surgicalpharma-companiesdrug-designcancer
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | urogen.com |
|---|---|
| linkedin.com/company/11520884 | |
| YouTube | youtube.com/channel/UCfocvR6Si3Awb5beahHHlzg |
| Wikidata | wikidata.org/wiki/Q140045834 |
Identifiers & details
| Legal name | UroGen Pharma Ltd. |
|---|---|
| Former names | Theracoat, TheraCoat |
| Founded | 2004-4 |
| Employees (exact) | 291 |
| Offices | Princeton |
| Market cap | $1.1B |
| Status reason | Public on NASDAQ on May 2017; |
| Wikidata QID | Q140045834 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2017-05 | NASDAQ | URGN | $66.9M |
| Public Offering | 2018-01 | NASDAQ | URGN | $60.0M |
| Public Offering | 2024-06 | NASDAQ | URGN | $107.5M |
Radar intelligence
Patents
| EPO | 24 |
|---|
Publications (Crossref)
| Works | 2 |
|---|
Web history (Wayback)
| Domain | urogen.com |
|---|
Wikidata
| QID | Q140045834 |
|---|
Certificate / subdomain footprint
| Subdomains | 36 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513537621 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2004-04-28 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2022 |
| Active charges / liens | 0 |
| Registry events | 6 — charge (5), people (1) |
| Registered address | התעשיה 9 רעננה |
Recent registry events
| Date | Event |
|---|---|
| 2026-02-11 | סילוק שעבוד |
| 2026-02-11 | סילוק שעבוד |
| 2026-02-11 | סילוק שעבוד |
| 2026-03-09 | עדכון בעלי תפקידים |
| 2026-03-05 | רישום שעבוד |
| 2026-03-05 | רישום שעבוד |